Biotech Values

[p3analyze]

The LLY development effort of LY2189265 at best can be characterized as half-hearted judging by the number of trials it has launched: 9 for LY2189265 and 23 for Exenatide Once-weekly. When LY2189265 Phase III read out between 2012 and 2013, Bydureon would have at least a 2 to 3 year market lead time, not mentioning once-monthly. Either LLY was very confident that LY2189265 will clean Bydureon's clock or it really doesn't care.

http://clinicaltrials.gov/ct2/results?term=+LY2189265+
http://www.clinicaltrials.gov/ct2/results?term=exenatide+once+weekly